N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I:
1
Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-&agr; expression utilizing compounds of the present invention are also disclosed.
抑制 p38 激酶从而阻断细胞因子产生的 N-杂环化合物已被披露。在一种实施例中,本发明的化合物由式 I 表示。还披露了利用本发明化合物的生产方法、药物组合物以及治疗与不当 p38 激酶活性或 TNF-α 表达相关的疾病的方法。
N- heterocyclic inhibitors of TNF-alpha expression
申请人:——
公开号:US20020137747A1
公开(公告)日:2002-09-26
N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I:
1
Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-&agr; expression utilizing compounds of the present invention are also disclosed.
[EN] N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION<br/>[FR] INHIBITEURS N-HETEROCYCLIQUES DE L'EXPRESSION DE TNF-ALPHA
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2003002542A1
公开(公告)日:2003-01-09
N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula (I). Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-a expression utilizing compounds of the present invention are also disclosed.
[EN] CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS<br/>[FR] INHIBITEURS DE LA CYTOKINE, EN PARTICULIER DE TNF-ALPHA
申请人:PHARMACOPEIA INC
公开号:WO2001047897A1
公开(公告)日:2001-07-05
N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I. Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.